Molecular Partners AG is banking $62.5 million up front and could receive up to $1.4 billion more in development, regulatory and commercial milestones in its second ophthalmology deal with Allergan Inc. Read More
A new license, development and commercialization agreement between Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., and Paris-based Ispen SA will restructure the existing partnership between the firms and provide additional funding to Inspiration for development of hemophilia drugs IB1001 and OBI-1. Read More
To save time and money, the FDA is making its website the sole go-to source for its agreements with other federal and state departments, agencies and organizations. Read More
The frequent disconnect between academic research and reproducible results has long been a bugaboo in biotech. Now, the scientific marketplace Science Exchange, open access publisher PLOS and open data repository Figshare have banded together to create a platform for independent validation of academic medical research. Read More
• MediciNova Inc., of San Diego, agreed to sell $20 million in common stock to Aspire Capital Fund LLC over the next two years. The first sale will be for 606,060 shares of common stock for $1 million, or $1.65 per share, upon execution of the agreement. Read More
• NPS Pharmaceuticals Inc., of Bedminster, N.J., said it was notified by the FDA that its new drug application for Gattex (teduglutide) will be discussed at the meeting of the Gastrointestinal Drugs Advisory Committee on Oct. 16. Read More
• Ocular Therapeutix Inc., of Bedford, Mass., said its travoprost punctum plug will be tested in a pilot Phase II trial to examine a two-month sustained-release drug (OTX-TP2) for ocular hypertension and glaucoma. Read More
• GE Healthcare, of Princeton, N.J., said the label for contrast agent Optison (perflutren protein-Type A microspheres injectable suspension, USP) was updated to include warnings about serious cardiopulmonary reactions. Read More
• Eisai Inc., of Woodcliff Lake, N.J., reported results from a final pivotal Phase III trial, showing that once-daily, adjunctive perampanel improved seizure control and was acceptably tolerated in subjects 12 and older with refractory partial-onset seizures. Read More
